Volanesorsen reduced fasting triglyceride (TG) by 35-42% at 12 months, in patients with familial chylomicronaemia syndrome (FCS) who had completed index studies or were treatment-naïve.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
